Cytotoxic and Antiproliferative Activity of LASSBio-2208 and the Attempts to Determine Its Drug Metabolism and Pharmacokinetics In Vitro Profile
Inappropriate expression of histone deacetylase (HDAC-6) and deregulation of the phosphatidylinositol 3-kinase (PI3K) signalling pathway are common aberrations observed in cancers. LASSBio-2208, has been previously described as a dual inhibitor in the nanomolar range of HDAC-6 and PI3Kα and is three...
Saved in:
Main Authors: | Raysa Magali Pillpe-Meza (Author), Wesley Leandro Gouveia (Author), Gisele Barbosa (Author), Carlos A. M. Fraga (Author), Eliezer J. Barreiro (Author), Lidia Moreira Lima (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
by: Celina de Jesus Guimarães, et al.
Published: (2023) -
Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs
by: Gisele Barbosa, et al.
Published: (2022) -
Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet
by: Nadia Alice Vieira da Motta, et al.
Published: (2013) -
LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A2A Receptor
by: Vinicius F. Carvalho, et al.
Published: (2017) -
Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor
by: Rafaela R. Silva, et al.
Published: (2019)